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Abstract
Background: A combination of clinical and routine laboratory data with biomarkers reflecting different pathophysiological
pathways may help to refine risk stratification in heart failure (HF). A novel calculator (BCN Bio-HF calculator) incorporating
N-terminal pro B-type natriuretic peptide (NT-proBNP, a marker of myocardial stretch), high-sensitivity cardiac troponin T
(hs-cTnT, a marker of myocyte injury), and high-sensitivity soluble ST2 (ST2), (reflective of myocardial fibrosis and
remodeling) was developed.
Methods: Model performance was evaluated using discrimination, calibration, and reclassification tools for 1-, 2-, and 3-year
mortality. Ten-fold cross-validation with 1000 bootstrapping was used.
Results: The BCN Bio-HF calculator was derived from 864 consecutive outpatients (72% men) with mean age 68.2612 years
(73%/27% New York Heart Association (NYHA) class I-II/III-IV, LVEF 36%, ischemic etiology 52.2%) and followed for a median
of 3.4 years (305 deaths). After an initial evaluation of 23 variables, eight independent models were developed. The variables
included in these models were age, sex, NYHA functional class, left ventricular ejection fraction, serum sodium, estimated
glomerular filtration rate, hemoglobin, loop diuretic dose, b-blocker, Angiotensin converting enzyme inhibitor/Angiotensin-
2 receptor blocker and statin treatments, and hs-cTnT, ST2, and NT-proBNP levels. The calculator may run with the
availability of none, one, two, or the three biomarkers. The calculated risk of death was significantly changed by additive
biomarker data. The average C-statistic in cross-validation analysis was 0.79.
Conclusions: A new HF risk-calculator that incorporates available biomarkers reflecting different pathophysiological
pathways better allowed individual prediction of death at 1, 2, and 3 years.
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Introduction
Risk stratification of heart failure (HF) is a challenge, and as
guidelines acknowledge, new accurate scoring models are needed.
Several models have been developed [1–10], of which the Seattle
HF model [6] has had the most visibility. Nevertheless, this scoring
model is derived from a cohort of patients carefully selected for a
randomized clinical trial over 20 years ago, with its inclusion and
exclusion criteria. Serum biomarkers for patient risk stratification
were not available. However, in recent times a number of
biomarkers reflective of different pathophysiological pathways
have been identified in HF [11]. Therefore, we developed a
calculator for HF stratification that, in addition to classical risk
factors, includes N-terminal pro B-type natriuretic peptide (NT-
proBNP), a marker of myocardial stretch; high-sensitivity cardiac
troponin T (hs-cTnT), a marker of myocyte injury; and high-
sensitivity soluble ST2 (ST2), which is reflective of myocardial
fibrosis and remodeling.
The Barcelona Bio Heart Failure risk calculator (BCN Bio-HF
calculator), which is derived from a real-life cohort of contempo-
rary treated HF patients, is a web-based calculator allowing quick
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85466
and easy interactive calculations of individual mortality at 1, 2,
and 3 years and life expectancy.
Methods
Derivation Study Population
The study population, samples, and biomarker assays were
described elsewhere [12]. In summary ambulatory patients treated
at a multidisciplinary HF unit were consecutively included in the
study in an outpatient setting. Patients were referred to the unit by
cardiology or internal medicine departments and, to a lesser
extent, from the emergency or other hospital departments. The
principal referral criterion was HF according to the European
Society of Cardiology guidelines irrespective of etiology, at least
one HF hospitalization, and/or reduced LVEF. Etiologies of HF
were: ischemic heart disease 52.2%, dilated cardiomyopathy 10%,
hypertensive 9.4%, alcoholic cardiomyopathy 5.7%, drug-related
cardiomyopathy 2.5%, valvular disease 11.4% and others 8.8%.
All participants provided written informed consent, and the
local ethics committee approved the study. All study procedures
were in accordance with the ethical standards outlined in the
Helsinki Declaration of 1975 as revised in 1983. The regular
visitation schedule was reported elsewhere [12–15]. Death from all
causes was the main outcome. Fatal events were identified from
clinical records, family contact or by reviewing the electronic
clinical history at the Catalan and Spanish Institute of Health.
Physicians and nurses of the HF Unit identified adverse events (JL,
M de A, AU, BG, RC, LC).
Model Making
A selection of 23 well-known mortality-related variables from
the literature and from previous own studies was first evaluated,
and 11 of them were included in eight Cox proportional hazard
regression models due to their significance in the multivariate
analysis or because considered of clinical significant relevance: one
model without biomarkers (‘clinical model’) and seven additional
models with all possible combinations of the three biomarkers.
Proportional assumptions needed to use Cox proportional
hazard regression models were tested for all variables. Variables in
which the non-linear component achieved significance were
transformed according to what the figure of time vs. hazard
suggested until non-significance of the non-linear component was
achieved, as reported elsewhere [12,14,15]. In summary, to fulfill
the assumption of linearity for the co-variables hs-cTnT, ST2, and
NT-proBNP, the logarithmic functions of both NT-proBNP and
hs-cTnT, the quadratic term of the logarithmic function of hs-
cTnT, and the quadratic term of ST2 were used in the Cox
proportional hazard regression models. In the ‘clinical model’,
variables were removed one-by-one in a backward manner to
assess whether their exclusion significantly reduced the likelihood
of the model. When two variables were collinear in predicting
outcome, the one with the better likelihood was included. All two-
variable interactions were also tested. Some variables were
dichotomized (such as New York Heart Association (NYHA)
functional class or left ventricular ejection fraction (LVEF) for
better performance).
Model Performance
We used different measures of performance to test the potential
incremental prognostic value of the three biomarkers as follows:
Discrimination. The ability of the model to discriminate
between patients who will have and will not have the event along
all follow-up was measured by means of the C-statistic obtained
from a generalization of Somers ‘Dxy’ rank correlation, which
equals 26(c21/2), where c is the concordance (discrimination)
probability [16], which already incorporates information from
censored data.
Calibration. How well the observed incidence rate fit the
predicted risk was measured by Nam-D’Agostino statistics using
the Hosmer and Lemeshow test for censored survival [17].
Calibration using this method was calculated for one-, two- and
three-year mortality.
Accuracy. The integrated Brier score for censored observa-
tions was used to measure the accuracy of probabilistic predictions
[18]. A lower score represents higher accuracy. This score takes
values between 0 and 1 and was calculated for one-, two- and
three-year mortality.
Best prediction. The Bayesian information criterion (BIC)
and the Akaike information criterion (AIC), measures of the
relative goodness-of-fit of a statistical model, were used to compare
non-nested models. Lower values indicate a better model along all
follow-up. Both indicators take into account the events along all
follow-up.
Reclassification. We used the method described by Pencina
et al. [19]. Integrated discrimination improvement (IDI) considers
changes in the estimated mortality prediction probabilities as a
continuous variable. Net reclassification improvement (NRI)
requires a previous definition of meaningful risk categories; we
used tertiles for the risk of death: ,18.5%, 18.5–41%, and .41%.
NRI considers changes in the predicted probabilities of estimated
mortality that imply a change from one category to another.
Reclassification was evaluated for one-, two- and three-year
mortality.
Generalization or validation. To assess how the results of
the models can be generalized to an independent data set, a 10-
fold cross-validation technique was used [20]. Using a boot-
strapping technique, we created 1000 samples (allowing repetition)
equal in size to the present cohort. One by one, each of the 1000
samples was split into 10 distinct blocks roughly equal in size. We
left out the first block (the testing set) and fit a model with the
remaining blocks (the training set) to predict the held-out-block.
We continued this process until the model predicted all 10 held-
out-blocks. The mean C-statistic was calculated and the process
repeated for all 1000 samples.
Calculator algorithms
Mortality. The calculator was designed to run with the
availability of none, one, two, or three of the chosen biomarkers,
using the best model for each available combination. To calculate
the probability of developing an event at a specific time, the
following formula was applied:
p^(Tvtj~xi)~1{S^(t)exp
( b
!
xi!){( b! x!)
Where:
N p^(Tvtj~xi) = probability to develop the event at time ‘‘T’’
before time ‘‘t’’ (e.g., 3 years) giving a combination ‘‘~xi’’ of
patient characteristics (i.e., age, sex, etc.);
N S^(t) = estimated survival at time ‘‘t’’;
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N ( b! xi!) = the vector of beta coefficients (natural log of the
hazard ratio (HR)) multiplied by the vector of patient
characteristics;
N ( b! x!) = the vector of beta coefficients multiplied by the
vector of mean covariates;
Life expectancy. To get an estimate of life expectancy we
refitted all Proportional Hazard Cox-Regression models in
parametric Weibull models [21]. In those models the mean
survival, ‘‘E(T)’’, is estimated by:
E(T)~ exp (m^zb^0x)C(1zs^)
where,
m^ is the estimated intercept obtained from the model
Table 1. Demographic, clinical and analytical characteristics of patients.
NO EVENT EVENT Univariate analysis
Multivariate analysis
without biomarkers
Multivariate analysis with
biomarkers
N = 559 N = 305
HRCox P-value HRCox P-value HRCox P-value
Age, years 64.6 (12.3) 74.4 (9.23) 1.07 [1.06;1.08] ,0.001 1.04 [1.03;1.06] ,0.001 1.04 [1.02;1.06] ,0.001
Female Gender 149 (26.7%) 93 (30.5%) 1.07 [0.84;1.36] 0.590 0.66 [0.5;0.89] 0.005 0.77 [0.57;1.03] 0.078
BMI, Kg/m2 28.0 (4.95) 27.0 (5.15) 0.96 [0.93;0.98] ,0.001 1.00 [0.97;1.02] 0.724 1.01 [0.98;1.04] 0.695
NYHA III–IV 91 (16.3) 144 (47.2) 3.25 [2.59;4.07] ,0.001 1.87 [1.45;2.42] ,0.001 1.67 [1.29;2.17] ,0.001
LVEF,% 35.6 (13.0) 36.5 (15.0) 1.00 [0.99;1.01] 0.801
LVEF .45% 122 (21.8%) 76 (24.9%) 0.98 [0.75;1.28] 0.905 0.76 [0.54;1.06] 0.108 0.95 [0.67;1.34] 0.770
Ischemic etiology of HF 286 (51.2%) 165 (54.1%) 1.06 [0.84;1.32] 0.633 1.22 [0.92;1.6] 0.162 1.14 [0.86;1.5] 0.365
Systolic Blood Pressure, mmHg 127 (23.1) 127 (22.9) 1.00 [0.99;1.00] 0.775 1.00 [0.99;1.00] 0.605 1.00 [0.99;1.01] 0.872
Heart rate, bpm 68.9 (13.5) 70.7 (13.7) 1.01 [1.00;1.02] 0.004 1.00 [0.99;1.01] 0.469 0.99 [0.9;1] 0.115
Diabetes mellitus 181 (32.4%) 129 (42.3%) 1.42 [1.14;1.79] 0.002 1.26 [0.98;1.63] 0.070 1.2 [0.93;1.55] 0.166
Atrial fibrillation 82 (14.7%) 63 (20.7%) 1.49 [1.13;1.97] 0.004 1.09 [0.8;1.48] 0.583 0.96 [0.7;1.32] 0.796
Hypertension 327 (58.5%) 200 (65.6%) 1.31 [1.04;1.66] 0.024 0.97 [0.74;1.27] 0.836 0.89 [0.68;1.16] 0.388
Sodium, mmol/L 139 (3.22) 139 (3.79) 0.94 [0.90;0.97] ,0.001 0.94 [0.91;0.97] ,0.001 0.96 [0.93;1] 0.03
COPD 71 (12.7%) 73/23.9%) 1.69 [1.30;2.20] ,0.001 1.11 [0.83;1.5] 0.480 1.08 [0.79;1.47] 0.633
eGFR, ml/min/1.73m2 52.0 (24.2) 35.8 (16.7) 0.97 [0.96;0.97] ,0.001 0.99 [0.98;1] 0.019 1 [0.99;1.01] 0.800
Hemoglobin, g/dl 13.3 (1.72) 12.3 (1.81) 0.77 [0.72;0.82] ,0.001 0.90 [0.84;0.97] 0.008 0.92 [0.85;0.99] 0.035
Iron defficiency 260 (46.8%) 174 (57.2%) 1.42 [1.13;1.79] 0.002 1.06 [0.83;1.36] 0.627 0.98 [0.76;1.26] 0.847
ACEI or ARB 523 (93.6%) 251 (82.6%) 0.35 [0.26;0.47] ,0.001 0.69 [0.49;0.95] 0.024 0.91 [0.63;1.31] 0.601
Beta-Blocker 523 (93.6%) 233 (76.4%) 0.35 [0.27;0.45] ,0.001 0.58 [0.42;0.79] ,0.001 0.61 [0.44;0.84] 0.003
Statins 420 (75.1%) 172 (56.4%) 0.50 [0.40;0.63] ,0.001 0.57 [0.43;0.74] ,0.001 0.61 [0.46;0.81] ,0.001
Loop diuretic dose:
0 (no loop diuretic) 107 (19.1%) 26 (8.52%) Ref. Ref. Ref. Ref. Ref. Ref.
Dose 1{ 361 (64.6%) 172 (56.4%) 1.81 [1.20;2.73] 0.005 1.27 [0.81;2] 0.291 1.26 [0.69;1.16] 0.384
Dose 2` 91 (16.3%) 107 (35.1%) 3.73 [2.43;5.73] ,0.001 1.75 [1.07;2.97] 0.025 1.5 [0.9;2.48] 0.119
Spironolactone/eplerenone 225 (40.3%) 115 (37.7%) 1.03 [0.82;1.30] 0.780 1.02 [0.79;1.32] 0.864 0.89 [0.82;1.30] 0.780
CRT 31 (5.55%) 16 (5.25%) 0.84 [0.50;1.38] 0.483 0.92 [0.53;1.59] 0.761 0.85 [0.49;1.47] 0.558
ICD 66 (11.8%) 26 (8.52%) 0.69 [0.46;1.04] 0.074 1 [0.64;1.55] 0.988 0.96 [0.62;1.5] 0.867
Cystatin-C, mg/L 1.09 [0.90;1.39] 1.48 [1.15;1.93] 2.69 [2.21;3.28] ,0.001 1.15 [0.68;1.96] 0.602
Hs-cTnT, ng/L 15.7 [7.90;30.7] 34.1 [20.5;53.6] 11.6 [5.46;24.8] ,0.001 3.79 [1.62;8.85] 0.002
ST2, ng/mL 35.5 [29.4;45.5] 44.7 [33.9;60.0] 1.48 [1.34;1.65] ,0.001 1.23 [1.09;1.38] ,0.001
NTproBNP, ng/L 975 [361;2376] 2215 [935;5193] 1.61 [1.48;1.75] ,0.001 1.13 [0.99;1.29] 0.073
Data are expressed as mean (standard deviation), median [percentiles 25th–75th] or absolute number (percentage).
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BMI = body mass index; COPD: Chronic obstructive pulmonary disease; eGFR =
estimated glomerular filtration rate; HF, heart failure; hs-cTnT, high-sensitivity circulating troponin T; ST2 = high-sensitivity soluble ST2; LVEF = left ventricular ejection
fraction; NT-proBNP= N-terminal pro-brain natriuretic peptide; NYHA= New York Heart Association. CRT = cardiac resynchronization therapy; ICD= implantable
cardiac defibrillator.
Ref. = Reference.
{Loop diuretic dose 1: Furosemide-equivalent dose up to 40 mg/day or Torasemide up to 10 mg/day.
`Loop diuretic dose 2: Furosemide-equivalent dose .40 mg/day or Torasemide.10 mg/day.
The logarithmic functions of NTproBNP, hs-cTnT and cystatin C, the quadratic term of the logarithmic function of hs-cTnT, ST2 as ST2/10 and the quadratic term of ST2/
10 were used in the Cox models. P value for (ST2/10)2,0.001 in the univariate analysis and 0.006 in the multivariate analysis; P value for log(hs-cTnT)2,0.001 in the
univariate analysis and 0.015 in the multivariate analysis.
doi:10.1371/journal.pone.0085466.t001
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b^0x is the product of the coefficients and patient’s characteristics
C(1zs^) is call the gamma function of the 1 plus the estimated
‘‘scale’’ parameter obtained from the model.
Statistical analyses were performed using R software version
2.15.2. (http://www.R-project.org/).
Results
After an initial evaluation of 23 variables, eight models (one
without biomarkers and seven with combinations of the three
studied biomarkers) were finally included in the risk calculator
tool.
Table 1 provides the evaluated demographic, clinical, and
biochemical characteristics of the studied patients with univariate
and multivariate Cox regression analysis. During a median follow-
up of 3.4 years (25th-75th percentiles 1.8–5.0 years) 305 deaths
occurred. The follow-up for alive patients was 4.4 years (25th–75th
percentiles 2.7–5.2). The following variables emerged as significant
in at least one of the models: age, sex, NYHA functional class,
LVEF, estimated glomerular filtration rate (eGFR), serum sodium,
hemoglobin, daily loop diuretic dose, beta-blocker, angiotensin
converting enzyme inhibitor (ACEI)/angiotensin-2 receptor block-
er (ARB), statin treatment and hs-cTnT, ST2, and NTproBNP
levels. No pair-wise interaction between variables achieved
significance. Variables excluded from the models due to the lack
of statistical improvement in the model were: ischemic etiology of
HF, diabetes mellitus, body mass index, blood systolic pressure,
heart rate, atrial fibrillation, chronic obstructive pulmonary
disease, hypertension, iron deficiency, cystatin-C, spironolac-
tone/eplerenone treatment, cardiac resynchronization therapy
(CRT), and implantable cardiac defibrillator (ICD).
In the ‘clinical model’ (Model 1), LVEF (HR 0.69, P = 0.016),
eGFR (HR 0.99, P = 0.017), and ACEI/ARB treatment (HR 0.67,
P = 0.014) were significant outcome predictors. In the other
models, these variables often lost significance after the addition of
biomarkers. In Model 8, in which the predictors were adjusted for
the three biomarkers, age (HR 1, P,0.001) and NYHA functional
class (HR 1.67, P,0.001) remained strong risk factors, whereas
female sex (HR 0.75, P = 0.029), statin treatment (HR 0.67,
P = 0.001), serum sodium (HR 0.96, P = 0.036), plasma hemoglo-
bin (HR 0.91, P = 0.006), and beta-blocker treatment (HR 0.60,
P,0.001) showed a significant protective effect. The three
biomarkers exhibited a relationship with mortality, but in model
8, NTproBNP only showed a prognostic trend (Log(hs-TnT): HR
3.38, P = 0.002; ST2/10: HR 1.23, P,0.001; and Log(NT-
proBNP): HR 1.11, P = 0.078).
To calculate the probabilities to develop an event at specific
time for a particular covariates combination, beta coefficients,
survival at the mean of covariates and the sum of the product of
coefficients per covariates mean are needed. Survival at the mean
of covariates was 94.2% at 1 year, 87.5% at 2 years and 80.2% at
3 years. The remaining values are shown in Table S1 in File S1.
When a covariate added no increased prognostic accuracy, it was
not included in the risk calculation. An example of calculator
functioning is shown in the appendix. Table 2 shows the C-statistic
for the ‘clinical model’ and all of the models containing biomarkers
(alone or in combination) in the derivation sample. The model
with the three biomarkers had a C-statistic of 0.794 (95% CI
0.77;0.817). Calibration for 1-, 2-, and 3-year mortality was good
(non-significant in the Hosmer and Lemeshow test) (Fig. 1).
Reclassification for 1-, 2-, and 3-year mortality was better in the
models containing more than one biomarker, with the highest
found using the combination of ST2 and hs-cTnT (Model 7;
Table 2). The best overall performance was observed with models
7 and 8 (Table 2).
A web-based calculator (Fig. 2) (www.BCNBioHFcalculator.cat)
has been developed, allowing interactive calculation of estimated
individual probability. A graphic with monthly mortality proba-
bilities is also available. Risk of death was found to be largely
influenced by biomarkers’ results. As a practical exemple a 68
year-old male in NYHA class III, LVEF 30%, sodium 130 mmol/
L, eGFR 45 ml/min/m2, hemoglobin 12 g/dl, taking 60 mg of
furosemide and on treatment with statins, ACEI and betablockers
had a risk of death of 22%, 42% and 60% at 1,2 and 3 years,
respectively. When adding the following biomarker levels: hs-
cTnT 14 ng/L, ST2 40 ng/mL and NTproBNP 900 ng/L, the
risk fell to 10%, 21% and 32%. However, if biomarker data had
been hs-cTnT 70 ng/L, ST2 140 ng/mL, and NTproBNP
2500 ng/L the risk would rise to 35%, 62% and 80%, respectively
(Fig. S1).
In the 10-fold cross-validation analysis with 1000 bootstrapping,
the average C-statistic for the model with all combined biomarkers
was 0.79 (Fig. 3), suggesting that the results may be generalized
safely to independent data sets.
Mean (95% confidence interval) life expectancy for the entire
cohort was 11.8 years (11.1212.4) and expected mean age (95%
confidence interval) for death was 80.2 years (79.7280.7) using
clinical model; and 11.4 years (10.7212.0) and 79.8 years
Figure 1. Observed and predicted mortality according to risk deciles (Hosmer and Lemeshow test) at 1-year (A), 2-year (B), and 3-
year (C) follow-up for model 8 (with the three biomarkers).
doi:10.1371/journal.pone.0085466.g001
BCN Bio-HF Calculator
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e85466
T
a
b
le
2
.
P
e
rf
o
rm
an
ce
o
f
th
e
m
o
d
e
ls
.
C
li
n
ic
a
l
C
li
n
ic
a
l
m
o
d
e
l
C
li
n
ic
a
l
m
o
d
e
l
C
li
n
ic
a
l
m
o
d
e
l
C
li
n
ic
a
l
m
o
d
e
l
C
li
n
ic
a
l
m
o
d
e
l
C
li
n
ic
a
l
m
o
d
e
l
C
li
n
ic
a
l
m
o
d
e
l
M
o
d
e
l
+
N
T
p
ro
B
N
P
+
h
s-
cT
n
T
+
S
T
2
+
N
T
p
ro
B
N
P
+
N
T
p
ro
B
N
P
+
h
s-
cT
n
T
+
a
ll
b
io
m
a
rk
e
rs
+
S
T
2
+
h
s-
cT
n
T
+
S
T
2
C
-s
ta
ti
st
ic
0
.7
7
1
0
.
7
7
7
0
.7
8
2
0
.7
7
9
0
.7
8
5
0
.7
8
4
0
.7
9
2
0
.7
9
3
(0
.7
4
4
;0
.7
9
7
)
(0
.7
5
1
;0
.8
0
3
)
(0
.7
5
8
;0
.8
0
7
)
(0
.7
5
4
;0
.8
0
4
)
(0
.7
6
;0
.8
0
9
)
(0
.7
5
9
0
.8
0
9
)
(0
.7
6
8
;0
.8
1
5
)
(0
.7
7
;0
.8
1
7
)
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.0
5
2
P
-v
al
u
e
=
0
.0
6
1
P
-v
al
u
e
=
0
.0
9
8
P
-v
al
u
e
=
0
.0
1
5
P
-v
al
u
e
=
0
.0
2
1
P
-v
al
u
e
=
0
.0
0
3
P
-v
al
u
e
=
0
.0
0
1
H
-L 1
ye
ar
x
2
:
8
.3
x
2
:
4
.2
3
x
2
:
5
.5
4
x
2
:
5
.3
4
x
2
:
7
.5
1
x
2
:
4
.4
6
x
2
:
1
0
.6
x
2
:
8
.6
7
P
-v
al
u
e
=
0
.5
0
P
-v
al
u
e
=
0
.9
0
P
-v
al
u
e
=
0
.7
9
P
-v
al
u
e
=
0
.8
0
P
-v
al
u
e
=
0
.5
8
P
-v
al
u
e
=
0
.8
1
P
-v
al
u
e
=
0
.2
3
P
-v
al
u
e
=
0
.3
7
2
ye
ar
s
x
2
:
1
0
.6
x
2
:
6
.5
2
x
2
:
5
.8
2
x
2
:1
0
.0
3
x
2
:1
0
.8
9
x
2
:
7
.4
1
x
2
:8
.0
3
x
2
:7
.4
6
P
-v
al
u
e
=
0
.3
1
P
-v
al
u
e
=
0
.6
9
P
-v
al
u
e
=
0
.7
6
P
-v
al
u
e
=
0
.3
5
P
-v
al
u
e
=
0
.2
8
P
-v
al
u
e
=
0
.4
9
P
-v
al
u
e
=
0
.4
3
P
-v
al
u
e
=
0
.4
9
3
ye
ar
s
x
2
:1
0
.4
x
2
:
5
.1
6
x
2
:7
.6
3
x
2
:1
4
.8
7
x
2
:1
1
.2
0
x
2
:1
1
.1
5
x
2
:7
.5
3
x
2
:7
.7
8
P
-v
al
u
e
:0
.3
2
P
-v
al
u
e
:0
.8
2
P
-v
al
u
e
:0
.5
7
P
-v
al
u
e
:0
.0
9
4
P
-v
al
u
e
:0
.2
6
P
-v
al
u
e
:0
.1
9
P
-v
al
u
e
:0
.4
8
P
-v
al
u
e
:0
.4
6
B
ri
e
r
sc
o
re
1
ye
ar
0
.2
5
2
0
.2
5
1
0
.2
5
0
0
.2
5
0
0
.2
4
9
0
.2
4
9
0
.2
4
7
0
.2
4
7
2
ye
ar
s
0
.1
9
8
0
.1
9
5
0
.1
9
3
0
.1
9
3
0
.1
9
2
0
.1
9
1
0
.1
8
8
0
.1
8
8
3
ye
ar
s
0
.1
6
9
0
.1
6
6
0
.1
6
3
0
.1
6
4
0
.1
6
1
0
.1
6
1
0
.1
5
7
0
.1
5
7
A
IC
3
4
7
0
3
4
5
5
3
4
4
0
3
4
5
5
3
4
4
1
3
4
3
5
3
4
2
1
3
4
2
1
B
IC
3
5
2
7
3
5
1
7
3
4
8
8
3
5
1
2
3
4
9
8
3
4
9
2
3
4
7
3
3
4
7
8
ID
I 1
ye
ar
2
0
.0
2
[2
0
.6
2
;0
.5
7
]
0
.4
5
[2
0
.1
8
;
1
.0
8
]
0
.5
7
[2
0
.1
2
;1
.2
6
]
0
.5
4
[2
0
.2
0
;1
.2
8
]
0
.5
9
[2
0
.0
3
;
1
.2
0
]
0
.9
7
[0
.1
5
;1
.8
0
]
0
.9
2
[0
.1
1
;1
.7
2
]
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.9
4
P
-v
al
u
e
=
0
.1
6
P
-v
al
u
e
=
0
.1
1
P
-v
al
u
e
=
0
.1
5
P
-v
al
u
e
=
0
.0
6
3
P
-v
al
u
e
=
0
.0
2
1
P
-v
al
u
e
=
0
.0
2
5
2
ye
ar
s
2
0
.0
2
[2
0
.9
2
;0
.8
8
]
1
.0
3
[0
.0
3
;
2
.0
4
]
0
.7
9
[2
0
.2
2
;
1
.7
9
]
0
.8
5
[2
0
.2
7
;
1
.9
7
]
1
.3
2
[0
.3
2
;
2
.3
1
]
1
.8
4
[0
.5
6
;
3
.1
1
]
1
.8
0
[0
.5
6
;
3
.0
4
]
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.9
7
2
P
-v
al
u
e
=
0
.0
4
4
P
-v
al
u
e
=
0
.1
2
6
P
-v
al
u
e
=
0
.1
3
6
P
-v
al
u
e
=
0
.0
0
9
P
-v
al
u
e
=
0
.0
0
5
P
-v
al
u
e
=
0
.0
0
5
3
ye
ar
s
0
.0
7
[2
1
.0
1
;1
.1
6
],
1
.5
2
[0
.2
7
;
2
.7
8
]
0
.8
6
[2
0
.3
2
;
2
.0
4
]
1
.1
2
[2
0
.2
2
;
2
.4
5
]
1
.9
5
[0
.7
0
;
3
.2
1
]
2
.5
5
[0
.9
9
;
4
.1
0
]
2
.5
7
[1
.0
5
;
4
.0
9
]
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.8
9
P
-v
al
u
e
=
0
.0
1
7
P
-v
al
u
e
=
0
.1
5
P
-v
al
u
e
=
0
.1
0
P
-v
al
u
e
=
0
.0
0
2
P
-v
al
u
e
=
0
.0
0
1
P
-v
al
u
e
=
,
0
.0
0
1
N
R
I 1
ye
ar
2
.3
4
[2
4
.2
9
;8
.9
7
]
7
.0
3
[2
0
.7
7
;1
4
.8
4
]
3
.9
6
[2
2
.5
5
;1
0
.4
7
]
1
1
.3
6
[4
.0
9
;1
8
.6
3
]
8
.4
7
[0
.9
5
;1
5
.9
9
]
1
0
.3
4
[1
.9
2
;1
8
.7
6
]
9
.5
8
[1
.4
9
;1
7
.6
6
]
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.4
8
9
P
-v
al
u
e
=
0
.0
7
7
P
-v
al
u
e
=
0
.2
3
3
P
-v
al
u
e
=
0
.0
0
2
P
-v
al
u
e
=
0
.0
2
7
P
-v
al
u
e
=
0
.0
1
6
P
-v
al
u
e
=
0
.0
2
2
ye
ar
s
2
.3
5
[2
4
.2
4
;8
.9
5
]
6
.8
3
[2
1
.0
0
;1
4
.6
6
]
3
.9
6
[2
2
.5
5
;1
0
.4
7
]
1
0
.6
3
[3
.2
7
;1
7
.9
8
]
7
.9
6
[0
.3
3
;1
5
.5
9
]
1
0
.0
9
[1
.6
4
;1
8
.5
3
]
8
.8
0
[0
.7
7
;1
6
.8
2
]
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.4
8
P
-v
al
u
e
=
0
.0
8
7
P
-v
al
u
e
=
0
.2
3
P
-v
al
u
e
=
0
.0
0
5
P
-v
al
u
e
=
0
.0
4
1
P
-v
al
u
e
=
0
.0
1
9
P
-v
al
u
e
=
0
.0
3
2
3
ye
ar
s
2
.1
5
[2
4
.4
2
;8
.7
3
]
7
.0
9
[2
0
.8
0
;1
4
.9
7
]
3
.7
4
[2
2
.8
0
;1
0
.2
8
]
1
0
.9
2
[3
.6
3
;1
8
.2
1
]
7
.9
6
[0
.3
5
;1
5
.5
7
]
9
.7
6
[1
.2
3
;1
8
.2
8
]
8
.9
3
[0
.9
5
;1
6
.9
2
]
R
e
fe
re
n
ce
P
-v
al
u
e
=
0
.5
2
P
-v
al
u
e
=
0
.0
7
8
P
-v
al
u
e
=
0
.2
6
P
-v
al
u
e
=
0
.0
0
3
P
-v
al
u
e
=
0
.0
4
P
-v
al
u
e
=
0
.0
2
5
P
-v
al
u
e
=
0
.0
2
8
x
2
=
C
h
i-
Sq
u
ar
e
.
P
va
lu
e
s
vs
M
o
d
e
l
1
(C
lin
ic
al
).
A
IC
=
A
ka
ik
e
in
fo
rm
at
io
n
cr
it
e
ri
o
n
;
B
IC
=
B
ay
e
si
an
in
fo
rm
at
io
n
cr
it
e
ri
o
n
;
H
L
=
H
o
sm
e
r–
Le
m
e
sh
o
w
te
st
;
h
s-
cT
n
T
,=
h
ig
h
-s
e
n
si
ti
vi
ty
ci
rc
u
la
ti
n
g
tr
o
p
o
n
in
T
;
ST
2
=
h
ig
h
-s
e
n
si
ti
vi
ty
so
lu
b
le
ST
2
;
ID
I=
in
te
g
ra
te
d
d
is
cr
im
in
at
io
n
im
p
ro
ve
m
e
n
t;
N
R
I=
n
e
t
re
cl
as
si
fi
ca
ti
o
n
im
p
ro
ve
m
e
n
t.
N
T
-p
ro
B
N
P
=
N
-t
e
rm
in
al
p
ro
-b
ra
in
n
at
ri
u
re
ti
c
p
e
p
ti
d
e
.
M
o
d
e
l
1
(C
lin
ic
al
)
=
A
g
e
,
Fe
m
al
e
,
N
Y
H
A
fu
n
ct
io
n
al
cl
as
s
(a
s
I2
II
vs
III
2
IV
),
LV
EF
(a
s
$
vs
,
4
5
%
),
e
G
FR
(e
st
im
at
e
d
g
lo
m
e
ru
la
r
fi
lt
ra
ti
o
n
ra
te
),
So
d
iu
m
,
H
e
m
o
g
lo
b
in
,
Fu
ro
se
m
id
e
-e
q
u
iv
al
e
n
t
d
o
se
s
tr
e
at
m
e
n
t
as
0
,
#
4
0
m
g
/d
ay
an
d
.
4
0
m
g
/d
ay
o
r
T
o
ra
se
m
id
e
as
0
,
#
1
0
m
g
/d
ay
an
d
.
1
0
m
g
/d
ay
),
A
C
EI
o
r
A
R
B
tr
e
at
m
e
n
t,
b
e
ta
-b
lo
ck
e
r
tr
e
at
m
e
n
t,
st
at
in
tr
e
at
m
e
n
t.
M
o
d
e
l
2
=
M
o
d
e
l
1
+N
T
-p
ro
B
N
P
.
M
o
d
e
l
3
=
M
o
d
e
l
1
+h
s-
cT
n
T
.
M
o
d
e
l
4
=
M
o
d
e
l
1
+S
T
2
.
M
o
d
e
l
5
=
M
o
d
e
l
1
+N
T
-p
ro
B
N
P
+S
T
2
.
M
o
d
e
l
6
=
M
o
d
e
l
1
+N
T
-p
ro
B
N
P
+h
s-
cT
n
T
.
M
o
d
e
l
7
=
M
o
d
e
l
1
+h
s-
cT
N
T
+S
T
2
.
M
o
d
e
l
8
=
M
o
d
e
l
1
+N
T
-p
ro
B
N
P
+h
s-
cT
N
T
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
8
5
4
6
6
.t
0
0
2
BCN Bio-HF Calculator
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e85466
(79.3280.3) with Model 8 (containing the three biomarkers),
respectively. Beta-coefficients of the different Weibull models used
to calculate life expectancy are shown in Table S2 in File S1.
Discussion
HF risk prediction is a cornerstone of HF management. The
development of an accurate HF risk calculator has the potential for
tailored management. The BCN Bio-HF calculator reported here
was derived from a real-life contemporarily treated consecutive
cohort and includes, in addition to conventional prediction factors,
three serum biomarkers (NTproBNP, ST2, and hs-cTnT) that are
highly accurate for cardiac malfunction.
Mortality risk prediction models specific to the HF population
have been developed with broad variation in the degree of
validation and concretion of prognostic output, from classification
into risk groups (low-high risk, low-medium-high risk, risk deciles)
[225], to life expectancy [6] or individual mortality at a certain
time point [3,527,10]. Most of these models have not included a
substantial proportion of patients taking evidence-based treat-
ments, including ACEI/ARBs, beta-blockers, and spironolactone/
eplerenone, or were developed only for patients admitted to the
hospital [8,9]. In the Seattle HF Model, the relative effect for HF
medications could not be obtained from the derivation cohort and
benefits were estimated from published trials or meta-analyses. In
our cohort of ambulatory patients, 87% were on beta-blockers,
90% on ACEI/ARBs, and 40% on spironolactone/eplerenone.
Independent of the causality of the risks and benefits of treatments,
taking evidence-based HF drugs clearly reduces the risk of death,
and they merit inclusion in a risk calculator. In fact, the estimated
risk can be very significantly modified by treatment, both in the
model without biomarkers and in the model containing biomark-
ers where treatment can also modify their level and the calculated
risk of death would consequently change.
Some scores [426] have the advantage of a large derivation
cohort. Their limitation is that all of the subjects in their derivation
and validation samples were participating in a clinical trial and
how well they represent those in routine clinical practice is
unknown. In addition, all of the samples were obtained over a
decade ago, and none included biomarker testing. The very recent
3C-HF score [7] did include contemporary treatment but not
biomarkers in a mixed population of in- and outpatients included
both prospectively and retrospectively. Also the even more recent
MAGGIC score, derived from a metaanalysis of 30 studies [10]
Figure 2. The Barcelona Bio-HF calculator has been implemented as an interactive program that employs the eight developed
models to estimate 1-, 2-, and 3-year mortality for an individual patient. This tool is available at www.BCNBioHFcalculator.cat.
doi:10.1371/journal.pone.0085466.g002
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did not include biomarkers. In the discussion, however, the
authors of this score state: ‘‘Any new risk score’s success depends
on the patient variables available for inclusion. Current knowledge
of biomarkers in HF is inevitably ahead of what data are available
across multiple cohort studies… but could not be included in our
model. In principle, its inclusion would enhance further the
excellent prognostic discrimination we achieved with routinely
collected longestablished predictors.’’ The inclusion of B-type
natriuretic peptide in the Valsartan-Heart Failure Trial to the
Seattle HF Model increased AUC by < 0.03 [6]. In the BCN Bio-
HF Calculator, we included three commercially available com-
plementary biomarkers that provide information about myocyte
necrosis (hs-cTnT), fibrosis, remodeling, and inflammation (ST2),
and chamber strain (NTproBNP). Other biomarkers are in the
pipeline for the HF field, but some of them are not yet
commercially available (i.e. growth differential factor-15) and
others reflect pathways that overlap those used here. We and
others previously reported on the prognostic utility of these three
biomarkers [12,14,15]. This calculator was developed with eight
models that include none, one, two, or the three biomarkers,
allowing its use with any combination of biomarkers. This
characteristic is unique to this new tool, which in combination
with the use of state-of-the-art statistics for biomarker values,
which include C-statistic, as well as calibration and reclassification,
makes it more robust.
The Seattle HF Model [6] is probably the most extensively used
model. It was prospectively validated in several trials. The
validation AUC varied from 0.68 to 0.81 in these diverse
populations, with an overall AUC of 0.73 and an AUC of less
than 0.70 in the three biggest cohorts [6]. AUC from other studies
rank from 0.75 (CHARM two-year mortality [4]) to 0.83 in the
validation cohort of the 3C-HF score (one-year mortality with
logistic regression analysis [5]). The use of Somers ‘Dxy’ rank
correlation in the C-statistic analysis, which already incorporates
information from censored data, is more correct from the survival
point of view rather than determination of C-statistic for death at
one fixed point with logistic regression models. The C-statistic
analysis using logistic regression model in our population was 0.82
for 1-year, 0.82 for 2-year and 0.83 for 3-year mortality. We
evaluated both the Seattle HF Model and the 3C-HF score in our
population. Taking into account the inherent limitations (default
values of Seattle HF for percentage of lymphocytes as well as
‘‘diabetes’’ instead of ‘‘diabetes with organ damage’’ for 3C-HF)
the C-statistic using Somers ‘Dxy’ rank correlation in such models
were 0.71 (95% CI 0.678-0.79) for the Seattle HF model and 0.73
(95% CI 0.68-0.73) for the 3C-HF score.
The validation obtained in our 10-fold cross-validation analysis
with 1000 bootstrapping was substantially higher, averaging 0.79.
Cross-validation is useful, especially when additional samples are
hazardous, costly, or impossible to collect. The resulting average
accuracy is likely somewhat of an underestimate for the true
accuracy when the model is trained on all data and tested on
external data (the optimal way for validation), but in most cases
this estimate is reliable, particularly if the amount of available data
is sufficiently large and the external data follows the same
distribution as the available data [22]. Both the Seattle HF Model
and the BCN Bio-HF calculator provide the individual risk of
death at several points of time without the necessity of a physician
calculating the score as an intermediate step. Also, as an added
value to other scores, both allow predicting life expectancy,
although using different statistical methods.
A number of the clinical variables in our calculator are also
included in the Seattle HF Model, though the former has fewer
variables. Some variables that may be considered clinically
important, such as devices, aldosterone blockers, and systolic
blood pressure, were excluded from our model due to the absence
of significance in the multivariable model. In the case of devices,
particularly ICD and CRT, the lack of significance could be
influenced by the limited number of patients with such devices.
Remarkably other variables such as blood pressure, ischemic
Figure 3. Ten-fold cross-validation with 1000 bootstrapping.
doi:10.1371/journal.pone.0085466.g003
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etiology and diabetes did not achieve statistical significance in the
multivariate analysis and did not improve the model prediction of
risk, and were not included in the calculator.
Recently, Ky et al.[23] showed that adding a more complex
biomarker panel consisting of high-sensitivity C-reactive protein,
myeloperoxidase, B-type natriuretic peptide, soluble fms-like
tyrosine kinase receptor-1, troponin I, ST2, creatinine, and uric
acid to the Seattle HF Model improves the predictive accuracy for
1-year all-cause death, with a C-statistic up to 0.8. In contrast,
both of our clinical and biomarker additive models were less
complex but performed similarly. Choosing the panel of
biomarkers to deploy in clinical practice will depend on factors
such as cost and ease of assay, among others.
Limitations
Our population was a general HF population treated at a HF
unit in a tertiary hospital. Most patients were white and referred
from the cardiology department and, thus, relatively young men
with HF of ischemic etiology and reduced LVEF. As such, risk
prediction is more accurate in these patients. The risk calculator is
based on ambulatory patients with chronic HF and may require
extensive adjustments when applied to an inpatient population,
some of whom have acute decompensated HF. Absence of
external validation represents an acknowledged limitation, al-
though we overcame it using 10-fold cross-validation analysis with
1000 bootstrapping as already discussed.
Conclusion
We developed a new HF risk calculator that incorporates
available biomarkers reflecting different pathophysiological path-
ways and allows quick and easy prediction of death at 1, 2, and 3
years.
Supporting Information
Figure S1 Graphic with monthly mortality probabilities in the
same patient (68 year- old male in NYHA class III, LVEF 30%,
sodium 130 mmol/L, eGFR 45 ml/min/m2, hemoglobin 12 g/
dl, taking 60 mg of furosemide and on treatment with statins,
ACEI and betablockers) according to model without biomarkers
(continuous line) and with biomarkers (dashed line). Left panel
biomarker values: hs-cTnT 14 ng/L and ST2 40 ng/mL and
NTproBNP of 900 ng/L. Righ panel biomarker values: hs-cTnT
70 ng/L, ST2 140 ng/mL and NTproBNP 2500 ng/L.
(TIF)
File S1 Supporting tables.
(DOC)
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